These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 37804179

  • 1. Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.
    Geertsema P, Koorevaar IW, Ipema KJR, Kramers BJ, Casteleijn NF, Gansevoort RT, Meijer E.
    Nephrol Dial Transplant; 2024 Mar 27; 39(4):707-716. PubMed ID: 37804179
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, Li H, Leonhard WN, Peters DJM, Qiu J, Touw DJ, Gansevoort RT, Meijer E.
    Clin J Am Soc Nephrol; 2022 Apr 27; 17(4):507-517. PubMed ID: 35314480
    [Abstract] [Full Text] [Related]

  • 4. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 27; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 5. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 6. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial.
    Bais T, Meijer E, Kramers BJ, Vart P, Vervloet M, Salih M, Bammens B, Demoulin N, Todorova P, Müller RU, Halbritter J, Paliege A, Gall EC, Knebelmann B, Torra R, Ong ACM, Karet Frankl FE, Gansevoort RT.
    Trials; 2024 Feb 14; 25(1):120. PubMed ID: 38355627
    [Abstract] [Full Text] [Related]

  • 7. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 14; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 8. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 9. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE, Minović I, van Faassen M, Kema IP, Boertien WE, Bakker SJL, van Beek AP, Gansevoort RT.
    Am J Nephrol; 2020 Dec 19; 51(11):861-870. PubMed ID: 33147589
    [Abstract] [Full Text] [Related]

  • 12. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
    Casteleijn NF, Messchendorp AL, Bae KT, Higashihara E, Kappert P, Torres V, Meijer E, Leliveld AM.
    Clin Exp Nephrol; 2017 Jun 19; 21(3):375-382. PubMed ID: 27339446
    [Abstract] [Full Text] [Related]

  • 13. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Aug 15; 18(1):268. PubMed ID: 28810844
    [Abstract] [Full Text] [Related]

  • 14. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.
    J Am Soc Nephrol; 2017 May 15; 28(5):1592-1602. PubMed ID: 27920153
    [Abstract] [Full Text] [Related]

  • 15. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K, Kitayama C, Yanai A, Ishibashi Y.
    Sci Rep; 2021 Sep 03; 11(1):17666. PubMed ID: 34480075
    [Abstract] [Full Text] [Related]

  • 16. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE.
    Eur J Pediatr; 2019 Jul 03; 178(7):1013-1021. PubMed ID: 31053954
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE, TEMPO 3:4 Investigators.
    Nephrol Dial Transplant; 2016 Nov 03; 31(11):1887-1894. PubMed ID: 26681730
    [Abstract] [Full Text] [Related]

  • 20. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.
    Kramers BJ, Koorevaar IW, Drenth JPH, de Fijter JW, Neto AG, Peters DJM, Vart P, Wetzels JF, Zietse R, Gansevoort RT, Meijer E.
    Kidney Int; 2020 Oct 03; 98(4):989-998. PubMed ID: 32534051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.